These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11875747)

  • 1. A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.
    de Graaf M; Boven E; Oosterhoff D; van der Meulen-Muileman IH; Huls GA; Gerritsen WR; Haisma HJ; Pinedo HM
    Br J Cancer; 2002 Mar; 86(5):811-8. PubMed ID: 11875747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pronounced antitumor efficacy by extracellular activation of a doxorubicin-glucuronide prodrug after adenoviral vector-mediated expression of a human antibody-enzyme fusion protein.
    de Graaf M; Pinedo HM; Oosterhoff D; van der Meulen-Muileman IH; Gerritsen WR; Haisma HJ; Boven E
    Hum Gene Ther; 2004 Mar; 15(3):229-38. PubMed ID: 15018732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
    Haisma HJ; Sernee MF; Hooijberg E; Brakenhoff RH; vd Meulen-Muileman IH; Pinedo HM; Boven E
    Blood; 1998 Jul; 92(1):184-90. PubMed ID: 9639515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and characterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human beta-glucuronidase.
    Haisma HJ; Brakenhoff RH; vd Meulen-Muileman I; Pinedo HM; Boven E
    Cancer Immunol Immunother; 1998 Jan; 45(5):266-72. PubMed ID: 9439650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted and tumour targeted human carboxylesterase for activation of irinotecan.
    Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR
    Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).
    Biela BH; Khawli LA; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Jun; 18(3):339-53. PubMed ID: 12954121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-glucuronidase-mediated drug release.
    de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
    Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
    J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
    Schanzer JM; Baeuerle PA; Dreier T; Kufer P
    Cancer Immun; 2006 Feb; 6():4. PubMed ID: 16483188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
    Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
    J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus.
    Sperker B; Mürdter TE; Backman JT; Fritz P; Kroemer HK
    Life Sci; 2002 Aug; 71(13):1547-57. PubMed ID: 12127909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane-localized activation of glucuronide prodrugs by beta-glucuronidase enzymes.
    Chen KC; Cheng TL; Leu YL; Prijovich ZM; Chuang CH; Chen BM; Roffler SR
    Cancer Gene Ther; 2007 Feb; 14(2):187-200. PubMed ID: 16977328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of novel anthracycline prodrugs activated by human beta-glucuronidase for use in antibody-directed enzyme prodrug therapy.
    Houba PH; Leenders RG; Boven E; Scheeren JW; Pinedo HM; Haisma HJ
    Biochem Pharmacol; 1996 Aug; 52(3):455-63. PubMed ID: 8687500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells.
    Schanzer JM; Fichtner I; Baeuerle PA; Kufer P
    J Immunother; 2006; 29(5):477-88. PubMed ID: 16971804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
    Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and function of beta-glucuronidase in pancreatic cancer: potential role in drug targeting.
    Sperker B; Werner U; Mürdter TE; Tekkaya C; Fritz P; Wacke R; Adam U; Gerken M; Drewelow B; Kroemer HK
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Aug; 362(2):110-5. PubMed ID: 10961372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
    Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
    Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.
    Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK
    Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.